Cadrenal Therapeutics, Inc. (CVKD) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending December 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is held by 20 institutional firms.

• Cadrenal Therapeutics saw its institutional ownership percentage rose to 5.9% in December 2025 from 5.6% in September 2025.
• The company experienced a 29.02% quarterly change in institutional shares held, alongside an increase of 100.00% in total owners annually.
• The latest 13F cycle for Cadrenal Therapeutics reveals that of 20 total investors, 7 funds grew their exposure, whereas 2 reduced theirs and 11 made no changes.
• The aggregate institutional position in Cadrenal Therapeutics now stands at 121.52K shares as of December 2025, after investors increased their holdings (up by 27.33K shares quarter on quarter which is up 106.68K shares year over year).
• VANGUARD GROUP INC continues to be the largest institutional holder of Cadrenal Therapeutics as of December 31, 2025, with a position of 53.91K shares, representing 2.63% of the company's outstanding stock.
• Among the most significant buyers of Cadrenal Therapeutics during December 2025 were DRW Securities, LLC (25.15K), GEODE CAPITAL MANAGEMENT, LLC (1.82K), UBS Group AG (1.01K), Tower Research Capital LLC (TRC) (532), MORGAN STANLEY (200).
• Leading sellers of Cadrenal Therapeutics stock in December 2025 included LPL Financial LLC (1.20K), VANGUARD GROUP INC (327).
• The top 10 institutional holders of Cadrenal Therapeutics for the quarter ending December 2025 included VANGUARD GROUP INC (53.91K), DRW Securities, LLC (25.15K), GEODE CAPITAL MANAGEMENT, LLC (14.53K), LPL Financial LLC (13.00K), JPMORGAN CHASE & CO (7.50K), BlackRock, Inc. (3.52K), MORGAN STANLEY (1.08K), UBS Group AG (1.04K), Tower Research Capital LLC (TRC) (532), OSAIC HOLDINGS, INC. (500).